3.69

4.24% 0.15

Pre-market: 3.69

Tvardi Therapeutics Inc (TVRD)

Overview News Price History Discussions Forecast

Tvardi Therapeutics Inc stock is traded at $3.69, with a volume of 41,041. It is up +4.24% in the last 24 hours and up +22.19% over the past month. Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.

Previous Close:

$3.54

Open:

$3.51

24h Volume:

41,041

Relative Volume:

0.81

Market Cap:

$34.62M

Revenue:

$2.57M

Net Income/Loss:

$-13.54M

P/E Ratio:

-0.6603

EPS:

-5.5882

Net Cash Flow:

$-23.50M

1W Performance:

+15.31%

1M Performance:

+22.19%

6M Performance:

-12.56%

1Y Performance:

-86.72%

1-Day Range:

$3.42

$3.755

1-Week Range:

$2.995

$3.755

52-Week Range:

$2.75

$43.65

Tvardi Therapeutics Inc Stock (TVRD) Company Profile

Name

Tvardi Therapeutics Inc

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

(713) 489-8654

Address

3 SUGAR CREEK CTR. BLVD., SUGAR LAND

Employee

Twitter

Next Earnings Date

2026-05-12

Latest SEC Filings

TVRD's Discussions on Twitter

Compare TVRD vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TVRD Tvardi Therapeutics Inc	3.69	34.62M	2.57M	-13.54M	-23.50M	-5.5882
VRTX Vertex Pharmaceuticals Inc	424.36	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.06B	5.36B	287.73M	924.18M	2.5229

Tvardi Therapeutics Inc Stock (TVRD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-20-26	Downgrade	Barclays	Equal Weight → Underweight
Oct-14-25	Downgrade	Barclays	Overweight → Equal Weight
Oct-14-25	Downgrade	Raymond James	Outperform → Mkt Perform
Oct-13-25	Initiated	Barclays	Overweight
Oct-13-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Oct-13-25	Downgrade	Piper Sandler	Overweight → Neutral
Jul-14-25	Initiated	Raymond James	Outperform
Jul-11-25	Initiated	Cantor Fitzgerald	Overweight
Jun-12-25	Initiated	Piper Sandler	Overweight
May-21-25	Initiated	Oppenheimer	Outperform
May-15-25	Initiated	BTIG Research	Buy
Jun-13-24	Downgrade	Canaccord Genuity	Buy → Hold
Jun-13-24	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-13-24	Downgrade	Needham	Buy → Hold
Jun-13-24	Downgrade	Stifel	Buy → Hold
Mar-08-23	Downgrade	BofA Securities	Neutral → Underperform
Mar-08-22	Upgrade	JP Morgan	Neutral → Overweight
Nov-01-21	Resumed	Canaccord Genuity	Buy
Aug-03-21	Initiated	JP Morgan	Neutral
Apr-21-20	Reiterated	H.C. Wainwright	Buy
Aug-12-19	Reiterated	H.C. Wainwright	Buy
May-29-19	Reiterated	Laidlaw	Buy
Feb-06-19	Resumed	Jefferies	Buy
Jan-15-19	Initiated	BofA/Merrill	Neutral
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Sep-13-18	Initiated	Jefferies	Buy
Aug-08-18	Reiterated	Stifel	Buy
Jun-28-18	Reiterated	H.C. Wainwright	Buy
Mar-12-18	Resumed	H.C. Wainwright	Buy
Feb-12-18	Upgrade	Janney	Neutral → Buy
Jan-19-18	Initiated	Seaport Global Securities	Buy

View All

Tvardi Therapeutics Inc Stock (TVRD) Latest News

May 04, 2026

MSN Money - MSN

May 04, 2026

May 02, 2026

Tvardi Therapeutics Files $200 Million Mixed Shelf - Moomoo

May 02, 2026

May 01, 2026

Tvardi Therapeutics (NASDAQ: TVRD) registers $200M shelf, $12.5M ATM - Stock Titan

May 01, 2026

Apr 29, 2026

Is Tvardi Therapeutics (TVRD) stock breaking out | Q4 2025: EPS Misses EstimatesInvestment Signal Network - Newser

Apr 29, 2026

Tvardi Therapeutics (TVRD) Price Target Decreased by 43.91% to 8.50 - MSN

Apr 29, 2026

Apr 26, 2026

TVRD Price Today: Tvardi Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange

Apr 26, 2026

Apr 24, 2026

Tvardi Therapeutics posts 18.3% downside EPS miss amid clinical trial costsEarnings Forecast - Newser

Apr 24, 2026

Apr 23, 2026

Tvardi Therapeutics (NASDAQ: TVRD) outlines 2026 votes on board, pay and auditors - Stock Titan

Apr 23, 2026

Apr 21, 2026

Barclays downgrades Tvardi Therapeutics (TVRD) - MSN

Apr 21, 2026

Apr 20, 2026

Tvardi Therapeutics Shares Drop After Downgrade From Barclays - Moomoo

Apr 20, 2026

Barclays Downgrades Tvardi Therapeutics to Underweight From Equalweight, Adjusts Price Target to $3 From $4 - Moomoo

Apr 20, 2026

Barclays cuts Tvardi Therapeutics stock rating on funding concerns - Investing.com

Apr 20, 2026

Barclays cuts Tvardi Therapeutics stock rating on funding concerns By Investing.com - Investing.com Canada

Apr 20, 2026

Apr 16, 2026